The Placebo used for the clinical trial is a sterile saline solution (0.9% w/v solution of NaCl in water) supplied in 1.25 mL pre-filled glass syringes., Shingrix suspension for injection in pre filled syringe Herpes zoster vaccine (recombinant, adjuvanted), Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted)
300889
Approved small_molecule active
Quick answer
The Placebo used for the clinical trial is a sterile saline solution (0.9% w/v solution of NaCl in water) supplied in 1.25 mL pre-filled glass syringes., Shingrix suspension for injection in pre filled syringe Herpes zoster vaccine (recombinant, adjuvanted), Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted) for Incident dementia is a Approved program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Incident dementia
- Phase
- Approved
- Modality
- small_molecule
- Status
- active